Diligence memo · auto-generated · as of July 2, 2026
Novellus, Inc.
Novellus, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Novellus, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Novellus, Inc. has raised $250K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $250K on 2014-05-23.
Most recent recorded round closed around 2014-05-23.
Valuation (modeled)modeled
Provath models Novellus, Inc. at approximately $12M (range $140K–$134M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.04× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era. Within the normal band (104% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 12.1 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 6% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 20% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.